Australian biotech Neuren Pharmaceuticals saw its share jump more than 22% to A$29.5 today, after it announced top-line results from its Phase II clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). 18 December 2023
US provider of chemical biology technologies Totus Medicines has announced the appointment of Nassim Usman as president and chief executive. 16 December 2023
Antibody specialist Nona Biosciences, a wholly-owned subsidiary of Hong Kong-based HBM Holdings, has entered into an exclusive license agreement with Pfizer. 15 December 2023
Shares in Californian rare disease company Reneo Pharmaceuticals have plummeted after the firm announced the failure of its pivotal STRIDE study. 15 December 2023
US biotech companies Biogen and Sage Therapeutics have announced that Zurvuvae (zuranolone) is now available by prescription for the treatment of postpartum depression (PPD) for adults in the USA. 14 December 2023
Allergy Therapeutics saw its share jump more than 8% to 2.10 pence by early afternoon as it released new data on its allergy candidate. 13 December 2023
Shares of US clinical-stage biotech C4 Therapeutics closed up a massive 98% on Tuesday and gained a further 12.8% to $2.64 pre-market, after the company announced a potentially lucrative deal with US pharma giant Merck & Co. 13 December 2023
Californian antibody specialist Electra Therapeutics has appointed Kathy Dong as president and chief executive, replacing current CEO Adam Rosenthal. 13 December 2023
Spanish dermatology specialist Almirall and etherna, a privately-held Belgian mRNA/lipid nanoparticle (LNP) technology platform company, have announced a collaboration. 12 December 2023
The US Federal Trade Commission (FTC) is seeking to block French pharma major Sanofi’s proposed acquisition of an exclusive license to Maze Therapeutics therapy in development for treatment of Pompe disease. 12 December 2023
Shares of USA-based Skye Bioscience rose 14% to $3.99 by mid-morning, after it revealed its intent to enter the huge and fast-growing obesity treatment sector. 11 December 2023
Privately-held Swiss drugmaker Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome have announced a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. 11 December 2023
The US Food and Drug Administration (FDA) on Friday approved two milestone treatments, Casgevy (exagamglogene autotemcel [exa-cel]), and Lyfgenia (lovotibeglogene autotemcel [lovo-cel)], representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD). 11 December 2023
Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the appointment of Angèle Maki, as chief business officer (CBO), with immediate effect. 11 December 2023
Shares of Intensity Therapeutics skyrocketed 120% to $8.79 pre-market today, after it announced positive safety, tolerability, efficacy and immune activation data from the company’s Phase II INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer. 9 December 2023
German biotech BioNTech revealed that it has signed a multi-year strategic partnership with the State of Victoria in Australia to strengthen the local mRNA ecosystem and facilitate innovations deriving from it. 8 December 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024